Sanofi: Libtayo® (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with ≥50% PD-L1 expression

Stacey Gandler
Brand Nourishment

Liz Kane
Impactful Strategy

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

Amy Giles
Increasing Engagement

Daniel Sontupe
Market Access

Suma Ramadas, PhD
Medical Affairs

David Linetsky
Point-of-Care Marketing

Joey Cohen
Medication Adherence

Bud Bilanich
Success Coach

Brenda Snow
Authentic Patient Voice

Paul Theisen
Patient Acquisition

Matthew Durham
Omnidynamic Marketing

Frank Burrell
Scientific Storytelling